Dr Wang will investigate and detail how leukaemic stem cells are able to survive and renew.
This research will pave the way for the development of a less invasive and personalised diagnostic tests to detect cancer relapse in children with ALL.
This project will narrow in on a specific gene regulation process known to play a role in the cancer development.
Dr Wang and her team have identified a new treatment target for one of the most lethal forms of leukaemia.
Dr Wong’s research is focused on the chemical changes in DNA and RNA that are associated with acute myeloid leukaemia.
Dr Micklethwaite and his team aim to create a new class of CAR T-cells that are capable of recognising and attacking acute myeloid leukaemia cells with a high degree of accuracy.
Prof David Gottlieb’s research has discovered that the treatment of using enhanced white blood cells to fight infection and leukemia can reduce side effects in bone marrow transplant recipients.
Genetically modified immune cells can be used to cure cases of leukaemia that are otherwise incurable. This project will optimise the technology to create cures for other types of cancer.
The aim of this 5 year program is to increase survival rates of children with Acute Lymphoblastic Leukaemia (ALL) and ultimately develop prevention strategies.
Professor Murray Norris and his team developed a pioneering tool that is improving the survival of children with leukaemia by stopping the cancer from returning.